WEKO3
アイテム
{"_buckets": {"deposit": "ba7459e5-24f0-4170-90fa-d3aa973c9165"}, "_deposit": {"created_by": 2, "id": "12913", "owners": [2], "pid": {"revision_id": 0, "type": "depid", "value": "12913"}, "status": "published"}, "_oai": {"id": "oai:nagasaki-u.repo.nii.ac.jp:00012913", "sets": ["30"]}, "author_link": ["47279", "47280", "47278", "47277"], "item_2_biblio_info_6": {"attribute_name": "書誌情報", "attribute_value_mlt": [{"bibliographicIssueDates": {"bibliographicIssueDate": "2010-11", "bibliographicIssueDateType": "Issued"}, "bibliographicIssueNumber": "11", "bibliographicPageEnd": "4574", "bibliographicPageStart": "4568", "bibliographicVolumeNumber": "54", "bibliographic_titles": [{"bibliographic_title": "Antimicrobial Agents and Chemotherapy"}]}]}, "item_2_description_4": {"attribute_name": "抄録", "attribute_value_mlt": [{"subitem_description": "Peramivir, a sialic acid analogue, is a selective inhibitor of neuraminidases produced by influenza A and B viruses. We evaluated the efficacy and safety of a single intravenous dose of peramivir in outpatients with uncomplicated seasonal influenza virus infection. A total of 300 previously healthy adult subjects aged 20 to 64 years with a positive influenza virus rapid antigen test were recruited within 48 h of the onset of influenza symptoms and randomized to three groups: single intravenous infusion of either 300 mg peramivir per kg of body weight, 600 mg peramivir, or matching placebo on study day 1. Influenza symptoms and body temperature were self-assessed for 14 days. Nasal and pharyngeal swabs were collected to determine the viral titer. The primary endpoint was the time to alleviation of symptoms. Of the 300 subjects, 296 were included in the intent-to-treat infected population (300 mg peramivir, n = 99; 600 mg peramivir, n = 97; and placebo, n = 100). Peramivir significantly reduced the time to alleviation of symptoms at both 300 mg (hazard ratio, 0.681) and 600 mg (hazard ratio, 0.666) compared with placebo (adjusted P value, 0.0092 for both comparisons). No serious adverse events were reported. Peramivir was well tolerated, and its adverse-event profile was similar to that of placebo. A single intravenous dose of peramivir is effective and well tolerated in subjects with uncomplicated seasonal influenza virus infection.", "subitem_description_type": "Abstract"}]}, "item_2_description_63": {"attribute_name": "引用", "attribute_value_mlt": [{"subitem_description": "Antimicrobial Agents and Chemotherapy, 54(11), pp.4568-4574; 2010", "subitem_description_type": "Other"}]}, "item_2_publisher_33": {"attribute_name": "出版者", "attribute_value_mlt": [{"subitem_publisher": "American Society for Microbiology"}]}, "item_2_relation_11": {"attribute_name": "PubMed番号", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "20713668", "subitem_relation_type_select": "PMID"}}]}, "item_2_relation_12": {"attribute_name": "DOI", "attribute_value_mlt": [{"subitem_relation_type": "isVersionOf", "subitem_relation_type_id": {"subitem_relation_type_id_text": "10.1128/AAC.00474-10", "subitem_relation_type_select": "DOI"}}]}, "item_2_rights_13": {"attribute_name": "権利", "attribute_value_mlt": [{"subitem_rights": "Copyright © 2010, American Society for Microbiology. All Rights Reserved."}]}, "item_2_source_id_10": {"attribute_name": "書誌レコードID", "attribute_value_mlt": [{"subitem_source_identifier": "AA00542574", "subitem_source_identifier_type": "NCID"}]}, "item_2_source_id_7": {"attribute_name": "ISSN", "attribute_value_mlt": [{"subitem_source_identifier": "00664804", "subitem_source_identifier_type": "ISSN"}]}, "item_2_source_id_8": {"attribute_name": "EISSN", "attribute_value_mlt": [{"subitem_source_identifier": "10986596", "subitem_source_identifier_type": "ISSN"}]}, "item_2_version_type_16": {"attribute_name": "著者版フラグ", "attribute_value_mlt": [{"subitem_version_resource": "http://purl.org/coar/version/c_ab4af688f83e57aa", "subitem_version_type": "AM"}]}, "item_creator": {"attribute_name": "著者", "attribute_type": "creator", "attribute_value_mlt": [{"creatorNames": [{"creatorName": "Kohno, Shigeru"}], "nameIdentifiers": [{"nameIdentifier": "47277", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Kida, Hiroshi"}], "nameIdentifiers": [{"nameIdentifier": "47278", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Mizuguchi, Masashi"}], "nameIdentifiers": [{"nameIdentifier": "47279", "nameIdentifierScheme": "WEKO"}]}, {"creatorNames": [{"creatorName": "Shimada, Jingoro"}], "nameIdentifiers": [{"nameIdentifier": "47280", "nameIdentifierScheme": "WEKO"}]}]}, "item_files": {"attribute_name": "ファイル情報", "attribute_type": "file", "attribute_value_mlt": [{"accessrole": "open_date", "date": [{"dateType": "Available", "dateValue": "2020-12-22"}], "displaytype": "detail", "download_preview_message": "", "file_order": 0, "filename": "AAC54_4568.pdf", "filesize": [{"value": "417.9 kB"}], "format": "application/pdf", "future_date_message": "", "is_thumbnail": false, "licensetype": "license_free", "mimetype": "application/pdf", "size": 417900.0, "url": {"label": "AAC54_4568.pdf", "url": "https://nagasaki-u.repo.nii.ac.jp/record/12913/files/AAC54_4568.pdf"}, "version_id": "b82cbbe3-56da-48c7-9dba-7320eca1e131"}]}, "item_language": {"attribute_name": "言語", "attribute_value_mlt": [{"subitem_language": "eng"}]}, "item_resource_type": {"attribute_name": "資源タイプ", "attribute_value_mlt": [{"resourcetype": "journal article", "resourceuri": "http://purl.org/coar/resource_type/c_6501"}]}, "item_title": "Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.", "item_titles": {"attribute_name": "タイトル", "attribute_value_mlt": [{"subitem_title": "Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection."}]}, "item_type_id": "2", "owner": "2", "path": ["30"], "permalink_uri": "http://hdl.handle.net/10069/27110", "pubdate": {"attribute_name": "公開日", "attribute_value": "2012-01-12"}, "publish_date": "2012-01-12", "publish_status": "0", "recid": "12913", "relation": {}, "relation_version_is_last": true, "title": ["Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection."], "weko_shared_id": 2}
Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection.
http://hdl.handle.net/10069/27110
http://hdl.handle.net/10069/27110c06a5365-610b-4c84-ae46-c3f989f2e4f1
名前 / ファイル | ライセンス | アクション |
---|---|---|
AAC54_4568.pdf (417.9 kB)
|
|
Item type | 学術雑誌論文 / Journal Article(1) | |||||
---|---|---|---|---|---|---|
公開日 | 2012-01-12 | |||||
タイトル | ||||||
タイトル | Efficacy and safety of intravenous peramivir for treatment of seasonal influenza virus infection. | |||||
言語 | ||||||
言語 | eng | |||||
資源タイプ | ||||||
資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
資源タイプ | journal article | |||||
著者 |
Kohno, Shigeru
× Kohno, Shigeru× Kida, Hiroshi× Mizuguchi, Masashi× Shimada, Jingoro |
|||||
抄録 | ||||||
内容記述タイプ | Abstract | |||||
内容記述 | Peramivir, a sialic acid analogue, is a selective inhibitor of neuraminidases produced by influenza A and B viruses. We evaluated the efficacy and safety of a single intravenous dose of peramivir in outpatients with uncomplicated seasonal influenza virus infection. A total of 300 previously healthy adult subjects aged 20 to 64 years with a positive influenza virus rapid antigen test were recruited within 48 h of the onset of influenza symptoms and randomized to three groups: single intravenous infusion of either 300 mg peramivir per kg of body weight, 600 mg peramivir, or matching placebo on study day 1. Influenza symptoms and body temperature were self-assessed for 14 days. Nasal and pharyngeal swabs were collected to determine the viral titer. The primary endpoint was the time to alleviation of symptoms. Of the 300 subjects, 296 were included in the intent-to-treat infected population (300 mg peramivir, n = 99; 600 mg peramivir, n = 97; and placebo, n = 100). Peramivir significantly reduced the time to alleviation of symptoms at both 300 mg (hazard ratio, 0.681) and 600 mg (hazard ratio, 0.666) compared with placebo (adjusted P value, 0.0092 for both comparisons). No serious adverse events were reported. Peramivir was well tolerated, and its adverse-event profile was similar to that of placebo. A single intravenous dose of peramivir is effective and well tolerated in subjects with uncomplicated seasonal influenza virus infection. | |||||
書誌情報 |
Antimicrobial Agents and Chemotherapy 巻 54, 号 11, p. 4568-4574, 発行日 2010-11 |
|||||
出版者 | ||||||
出版者 | American Society for Microbiology | |||||
ISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 00664804 | |||||
EISSN | ||||||
収録物識別子タイプ | ISSN | |||||
収録物識別子 | 10986596 | |||||
書誌レコードID | ||||||
収録物識別子タイプ | NCID | |||||
収録物識別子 | AA00542574 | |||||
PubMed番号 | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | PMID | |||||
関連識別子 | 20713668 | |||||
DOI | ||||||
関連タイプ | isVersionOf | |||||
識別子タイプ | DOI | |||||
関連識別子 | 10.1128/AAC.00474-10 | |||||
権利 | ||||||
権利情報 | Copyright © 2010, American Society for Microbiology. All Rights Reserved. | |||||
著者版フラグ | ||||||
出版タイプ | AM | |||||
出版タイプResource | http://purl.org/coar/version/c_ab4af688f83e57aa | |||||
引用 | ||||||
内容記述タイプ | Other | |||||
内容記述 | Antimicrobial Agents and Chemotherapy, 54(11), pp.4568-4574; 2010 |